France Hereditary Angioedema Therapeutic Market (2025-2031) | Analysis, Growth, Trends, Value, Outlook, Companies, Size & Revenue, Competitive Landscape, Forecast, Industry, Share, Segmentation

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 France Country Macro Economic Indicators

3.2 France Hereditary Angioedema Therapeutic Market Revenues & Volume, 2021 & 2031F

3.3 France Hereditary Angioedema Therapeutic Market - Industry Life Cycle

3.4 France Hereditary Angioedema Therapeutic Market - Porter's Five Forces

3.5 France Hereditary Angioedema Therapeutic Market Revenues & Volume Share, By Type, 2021 & 2031F

3.6 France Hereditary Angioedema Therapeutic Market Revenues & Volume Share, By Drug Class, 2021 & 2031F

3.7 France Hereditary Angioedema Therapeutic Market Revenues & Volume Share, By Application, 2021 & 2031F

3.8 France Hereditary Angioedema Therapeutic Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing awareness about hereditary angioedema (HAE) and its treatment options

4.2.2 Advancements in research leading to the development of new and more effective therapies

4.2.3 Rising prevalence of HAE cases in France

4.3 Market Restraints

4.3.1 High cost associated with HAE therapeutic treatments

4.3.2 Limited accessibility to specialized healthcare facilities for HAE patients in certain regions of France

4.3.3 Stringent regulatory requirements for approval of HAE therapies

6.1 France Hereditary Angioedema Therapeutic Market, By Type

6.1.1 Overview and Analysis

6.1.2 France Hereditary Angioedema Therapeutic Market Revenues & Volume, By Type, 2021- 2031F

6.1.3 France Hereditary Angioedema Therapeutic Market Revenues & Volume, By Type I Hereditary Angioedema (HAE), 2021- 2031F

6.1.4 France Hereditary Angioedema Therapeutic Market Revenues & Volume, By Type II Hereditary Angioedema (HAE), 2021- 2031F

6.1.5 France Hereditary Angioedema Therapeutic Market Revenues & Volume, By Type III Hereditary Angioedema (HAE), 2021- 2031F

6.2 France Hereditary Angioedema Therapeutic Market, By Drug Class

6.2.1 Overview and Analysis

6.2.2 France Hereditary Angioedema Therapeutic Market Revenues & Volume, By C-1 Esterase Inhibitors, 2021- 2031F

6.2.3 France Hereditary Angioedema Therapeutic Market Revenues & Volume, By Bradykynin B2 Receptor Antagonist, 2021- 2031F

6.2.4 France Hereditary Angioedema Therapeutic Market Revenues & Volume, By Kallikrein Inhibitors, 2021- 2031F

6.2.5 France Hereditary Angioedema Therapeutic Market Revenues & Volume, By Others, 2021- 2031F

6.3 France Hereditary Angioedema Therapeutic Market, By Application

6.3.1 Overview and Analysis

6.3.2 France Hereditary Angioedema Therapeutic Market Revenues & Volume, By Prophylaxis, 2021- 2031F

6.3.3 France Hereditary Angioedema Therapeutic Market Revenues & Volume, By Treatment, 2021- 2031F

6.4 France Hereditary Angioedema Therapeutic Market, By Route of Administration

6.4.1 Overview and Analysis

6.4.2 France Hereditary Angioedema Therapeutic Market Revenues & Volume, By Oral, 2021- 2031F

6.4.3 France Hereditary Angioedema Therapeutic Market Revenues & Volume, By Injectable, 2021- 2031F

7.1 France Hereditary Angioedema Therapeutic Market Export to Major Countries

7.2 France Hereditary Angioedema Therapeutic Market Imports from Major Countries

8.1 Average time to diagnosis of HAE patients in France

8.2 Number of clinical trials for new HAE therapies being conducted in France

8.3 Percentage of HAE patients in France receiving appropriate treatment and management

9.1 France Hereditary Angioedema Therapeutic Market Opportunity Assessment, By Type, 2021 & 2031F

9.2 France Hereditary Angioedema Therapeutic Market Opportunity Assessment, By Drug Class, 2021 & 2031F

9.3 France Hereditary Angioedema Therapeutic Market Opportunity Assessment, By Application, 2021 & 2031F

9.4 France Hereditary Angioedema Therapeutic Market Opportunity Assessment, By Route of Administration, 2021 & 2031F

10.1 France Hereditary Angioedema Therapeutic Market Revenue Share, By Companies, 2024

10.2 France Hereditary Angioedema Therapeutic Market Competitive Benchmarking, By Operating and Technical Parameters